DFTX Q2 2023 Earnings — Definium Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

$2B

Q2 2023 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$29M

Net Income

-$29M

EPS (Diluted)

$-0.76

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$142M

Total Liabilities

$36M

Stockholders' Equity

$106M

Cash & Equivalents

$117M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$29M	-$17M	-72.2%
Net Income	-$29M	-$17M	-71.8%